Literature DB >> 6196155

Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients.

R A Moggio, C C Rha, E D Somberg, P I Praeger, R W Pooley, G E Reed.   

Abstract

The hemodynamic effects of 2 plasma volume expanders were compared in postoperative open heart surgery patients. Albumin 5% (A) or hydroxyethyl starch 6% (HES) solutions were infused according to indications based on cardiac index (CI) and pulmonary wedge pressure (WP), and their effects evaluated by physiologic profile measurements. Both groups demonstrated significant increases with volume infusion in CI (A from 2.37 to 2.84; HES from 1.97 to 2.49 L/min X m2) and WP (A from 9.4 to 13.7 mm Hg; HES from 11.9 to 13.2 mm Hg). Stroke index and stroke work increased similarly. Mean systemic arterial pressure (MAP) and mean pulmonary arterial pressure (MPAP) remained unchanged. No significant difference for any variable was demonstrated between the A and HES groups. In the volume used, from 250 to 750 ml, HES caused no bleeding abnormalities. HES is as effective as A as a plasma volume expander in postoperative cardiac surgery patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196155     DOI: 10.1097/00003246-198312000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  12 in total

1.  Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery.

Authors:  Joanne Verheij; Arthur van Lingen; Albertus Beishuizen; Herman M T Christiaans; Jan R de Jong; Armand R J Girbes; Willem Wisselink; Jan A Rauwerda; Marinus A J M Huybregts; A B Johan Groeneveld
Journal:  Intensive Care Med       Date:  2006-05-23       Impact factor: 17.440

Review 2.  Hydroxyethyl starch for cardiovascular surgery: a systematic review of randomized controlled trials.

Authors:  Xue-Yin Shi; Zui Zou; Xing-Ying He; Hai-Tao Xu; Hong-Bin Yuan; Hu Liu
Journal:  Eur J Clin Pharmacol       Date:  2011-03-02       Impact factor: 2.953

3.  Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation.

Authors:  K Waxman; R Holness; G Tominaga; P Chela; J Grimes
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

4.  Polynitroxylated pegylated hemoglobin: a novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice.

Authors:  David K Shellington; Lina Du; Xianren Wu; Jennifer Exo; Vincent Vagni; Li Ma; Keri Janesko-Feldman; Robert S B Clark; Hülya Bayir; C Edward Dixon; Larry W Jenkins; Carleton J C Hsia; Patrick M Kochanek
Journal:  Crit Care Med       Date:  2011-03       Impact factor: 7.598

5.  Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution.

Authors:  J F Baron; D De Kegel; A C Prost; O Mundler; M Arthaud; G Basset; G Maistre; F Masson; A Carayon; C Landault
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 6.  Colloid solutions for fluid resuscitation.

Authors:  Frances Bunn; Daksha Trivedi
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 7.  Blood and plasma substitutes--plasma expansion and oxygen transport properties.

Authors:  K Waxman; K K Tremper; G R Mason
Journal:  West J Med       Date:  1985-08

Review 8.  Use of plasma volume expanders in myocardial revascularisation.

Authors:  J H Lacy; C B Wright
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers.

Authors:  J Waitzinger; F Bepperling; G Pabst; J Opitz; M Müller; J François Baron
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Albumin abuse in intensive care medicine.

Authors:  A F Grootendorst; M G van Wilgenburg; P H de Laat; B van der Hoven
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.